MedPage Today on MSN
Year in Review: Alzheimer's Disease
News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...
New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...
Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...
Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...
17hon MSN
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
MedPage Today on MSN
Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug
The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...
Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...
The actor’s National Geographic documentary shows the power of memory and social connection in supporting his father’s ...
An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results